Skip to main content
. 2022 Oct 31;3:31. doi: 10.21037/tbcr-22-35

Figure 4.

Figure 4

Prespecified exploratory subgroup analyses on BICR-assessed PFS. , only available for patients enrolled under protocol versions 1.0 and 2.0. HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; ISH, in situ hybridization; IHC, immunohistochemical; ER, estrogen receptor; PgR, progesterone receptor; BICR, blinded independent central review; PFS, progression-free survival.